Multiple Sclerosis and Neuroinflammation Center

The UCSF Multiple Sclerosis and Neuroinflammation Center is one of California's premier programs for evaluating, diagnosing and treating adult and pediatric patients with inflammatory diseases of the nervous system. Our knowledge and expertise in caring for patients with multiple sclerosis (MS) has won us designation as a comprehensive care center and as a Partner in MS Care from the National Multiple Sclerosis Society.

Our team includes renowned experts in neurology, neuro-ophthalmology, neuropsychology, infectious disease and rehabilitative medicine. They work closely with one another, as well as with specialists in other fields, to provide personalized, comprehensive care for patients with all types of neuroinflammatory disease. The state-of-the-art tools and services of our Neurodiagnostic Center allow us to evaluate patients' conditions in great detail and use the information to design the best treatment plan for each person. The goal is to help our patients manage their symptoms and stay as active, healthy and independent as possible. The team also serves as an educational and emotional support resource for patients and their families. Telemedicine follow-up visits are available for those who find them more convenient.

While striving to deliver the best possible patient care, we also are committed to advancing medical understanding of the causes of neuroinflammatory disease and to finding potential cures. USCF is a top recipient of research funding from the National Institutes of Health and National Multiple Sclerosis Society. Our doctors have been on the forefront of research into the causes of MS and studies to develop new treatments. Dr. Stephen Hauser, director of the UCSF Weill Institute for Neurosciences, was awarded the prestigious John Dystel Prize in 2008 for his pioneering studies on genetic susceptibility to MS. Other doctors at the center have helped develop breakthrough therapies, such as the drug ocrelizumab, a treatment for progressive MS approved by the Food and Drug Administration in 2017. Our patients often have the opportunity to take part in clinical trials, studies to evaluate promising therapies.

Our center is part of the UCSF Weill Institute for Neurosciences.